Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.
Back
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
Episodes
All
All
Alex Herrera, MD, discusses safety data and considerations for nivolumab plus AVD in classical hodgkin lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
European Commission Approves T-DXd Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
2
TP53 Status and Treatment Toxicity Burden Guide Sequencing in EGFR-Mutated NSCLC
3
August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know
4
New Biomarker-Driven Regimens Prompt Debate Over Treatment Intensification in Advanced Prostate Cancer
5